HomeDoravirine

Doravirine

Also known as: Pifeltro

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase InhibitorNon-Nucleoside Reverse Transcriptase Inhibitors

Route: Oral

Check Doravirine Interactions →
23 interactions on record

Doravirine has 23 known drug interactions based on U.S. FDA drug labeling data. Of these, 9 are contraindicated combinations that should be avoided entirely. 4 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbamazepine, Enzalutamide, Mitotane. Patients taking Doravirine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
23
Contraindicated
9
Major
4

Contraindicated (9)

  • Doravirine + CarbamazepineCo-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to
  • Doravirine + EnzalutamideAndrogen Receptors enzalutamide ↓ doravirine Co-administration is contraindicated with enzalutamide.
  • Doravirine + MitotaneCo-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to
  • Doravirine + OxcarbazepineCo-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to
  • Doravirine + PhenobarbitalCo-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to
  • Doravirine + PhenytoinCo-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to
  • Doravirine + RifampinCo-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to
  • Doravirine + RifapentineCo-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to
  • Doravirine + St. John'S WortCo-administration decreases doravirine plasma concentrations. At least a 4-week cessation period is recommended prior to

Major (4)

  • Doravirine + EfavirenzCo-administration decreases doravirine plasma concentrations. Use with efavirenz is not recommended.
  • Doravirine + EtravirineCo-administration decreases doravirine plasma concentrations. Use with etravirine is not recommended.
  • Doravirine + NevirapineCo-administration decreases doravirine plasma concentrations. Use with nevirapine is not recommended.
  • Doravirine + RifabutinCo-administration decreases doravirine plasma concentrations. Increase PIFELTRO dosage to one tablet twice daily when co
Doravirine + Dolutegravirℹ️Unknown

No clinically significant changes in concentration were observed for doravirine when co-administered with the following agents: dolutegravir, TDF, lamivudine, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ritonavir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, and methadone [see Clinical Pharmacology (12.3) ]. 7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3) ] .

Doravirine + Elbasvirℹ️Unknown

No clinically significant changes in concentration were observed for doravirine when co-administered with the following agents: dolutegravir, TDF, lamivudine, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ritonavir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, and methadone [see Clinical Pharmacology (12.3) ]. 7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3) ] .

Doravirine + Grazoprevirℹ️Unknown

No clinically significant changes in concentration were observed for doravirine when co-administered with the following agents: dolutegravir, TDF, lamivudine, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ritonavir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, and methadone [see Clinical Pharmacology (12.3) ]. 7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3) ] .

Doravirine + Ledipasvirℹ️Unknown

No clinically significant changes in concentration were observed for doravirine when co-administered with the following agents: dolutegravir, TDF, lamivudine, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ritonavir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, and methadone [see Clinical Pharmacology (12.3) ]. 7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3) ] .

Doravirine + Sofosbuvirℹ️Unknown

No clinically significant changes in concentration were observed for doravirine when co-administered with the following agents: dolutegravir, TDF, lamivudine, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ritonavir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, and methadone [see Clinical Pharmacology (12.3) ]. 7.2 Effect of PIFELTRO on Other Drugs No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see Clinical Pharmacology (12.3) ] .

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.